Publications by authors named "Mark Pullen"

Claim this Profile
P
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
Alan D Borthwick, John Liddle, Dave E Davies, Anne M Exall, Christopher Hamlett, Mark A Pullen

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.
Jian Jin, Angel Morales-Ramos, Patrick Eidam, John Mecom, Yue Li, Mark Pullen

ACS Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.
Mark A Hilfiker, Ning Wang, Xiaoping Hou, Zhimin Du, Mark A Pullen

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods.
Mark A Pullen, Mark R Harpel, Theodore M Danoff, David P Brooks

J Immunol Methods· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
John Liddle, Michael J Allen, Alan D Borthwick, David P Brooks, David E Davies, Mark A Pullen

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
Alexandra Hicks, Gerald P McCafferty, Erin Riedel, Nambi Aiyar, Mark Pullen

J Pharmacol Exp Ther· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
Gerald P McCafferty, Mark A Pullen, Charlene Wu, Richard M Edwards, Michael J Allen

Am J Physiol Regul Integr Comp Physiol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of conformational changes in the progesterone receptor using ELISA-like assays.
Mark A Pullen, Nicholas Laping, Richard Edwards, Jeffrey Bray

Steroids· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry.
César Ramírez-Molina, Olivier Heudi, Mark Pullen, Peter S Marshall

J Pept Sci· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
Anthony C Sulpizio, Mark A Pullen, Richard M Edwards, James B Louttit, Rob West

J Pharmacol Exp Ther· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats.
Jane Gartlon, Philip Szekeres, Mark Pullen, Henry M Sarau, Nambi Aiyar

Psychopharmacology (Berl)· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1.
Eric N Johnson, Edward R Appelbaum, Donald C Carpenter, Richard F Cox, Jyoti Disa, Mark A Pullen

J Immunol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Nambi Aiyar, Jyoti Disa, James J Foley, Peter T Buckley, William E Wixted, Mark Pullen

Pharmacology· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.
Mark A Pullen, David P Brooks, Richard M Edwards

J Pharmacol Exp Ther· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Anthony C Sulpizio, Mark A Pullen, Richard M Edwards, David P Brooks

J Pharmacol Exp Ther· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of endothelin on bladder contraction: potential role in bladder hyperactivity.
Timothy D Westfall, Gerald P McCafferty, Mark Pullen, Jessica Ventre, Marianne Eybye

Pharmacology· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat.
Christian T Abrahamsen, Mark A Pullen, Christine G Schnackenberg, Eugene T Grygielko, Richard M Edwards

Pharmacology· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of neuromedin U effects in canine smooth muscle.
Timothy D Westfall, Gerald P McCafferty, Mark Pullen, Susan Gruver, Anthony C Sulpizio

J Pharmacol Exp Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
Christian T Abrahamsen, Frank C Barone, Wallace G Campbell, Allen H Nelson, Lisa C Contino, Mark A Pullen

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis